Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2022 May 15.

Published in final edited form as: Clin Cancer Res. 2021 Sep 13;27(22):6174–6183. doi: 10.1158/1078-0432.CCR-21-0987

Table 1.

Association of OX40 positivity with clinicopathologic variables. Statistical analysis by Pearson Chi-Square test.

Variable	COHORT 1 (N=280)			COHORT 2 (N=207)

	OX40-positive	OX40-negative	p-value	OX40-positive	OX40-negative	p-value
	252 (90%)	28 (10%)		180 (87%)	27 (13%)
Age
≤ 70	154 (92%)	14 (8%)	0.325	130 (87%)	20 (13%)	0.607
> 70	96 (88%)	13 (12%)	0.325	35 (90%)	4 (10%)	0.607
Gender
Male	103 (87%)	16 (13%)	0.075	142 (87%)	22 (13%)	0.727
Female	146 (93%)	11 (7%)	0.075	21 (84%)	4 (16%)	0.727
Stage
Stage I-II	188 (90%)	21 (10%)	0.903	93 (84%)	18 (16%)	0.255
Stage III-IV	57 (90%)	6 (10%)	0.903	69 (90%)	8 (10%)	0.255
Histology
ADC	153 (91%)	15 (9%)	0.744	65 (90%)	7 (10%)	0.330
SCC	47 (89%)	6 (11%)		75 (82%)	16 (18%)
Others	43 (88%)	6 (12%)		23 (88%)	3 (12%)
Smoking status
Non/former smoker	125 (89%)	16 (11%)	0.479	16 (89%)	2 (11%)	0.761
Smoker	115 (91%)	11 (9%)	0.479	126 (86%)	20 (11%)	0.761